US Stock MarketDetailed Quotes
CUE Cue Biopharma
- 1.080
- -0.010-0.92%
Trading Nov 21 13:20 ET
68.42MMarket Cap-1186P/E (TTM)
1.095High1.020Low222.95KVolume1.090Open1.090Pre Close235.96KTurnover0.36%Turnover RatioLossP/E (Static)63.35MShares3.24952wk High2.70P/B67.88MFloat Cap0.45052wk Low--Dividend TTM62.86MShs Float31.690Historical High--Div YieldTTM6.88%Amplitude0.450Historical Low1.058Avg Price1Lot Size
Cue Biopharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 3.49%-7.53M | 3.67%-9.99M | 9.68%-9.78M | 4.41%-39.96M | -4.22%-10.96M | -13.51%-7.8M | 19.28%-10.37M | 6.39%-10.83M | -7.64%-41.81M | 1.23%-10.51M |
| Net income from continuing operations | 21.31%-8.66M | 22.86%-10.17M | 5.81%-12.35M | 4.30%-50.73M | 7.94%-13.43M | -0.46%-11.01M | 0.17%-13.19M | 8.04%-13.11M | -20.04%-53.01M | -74.04%-14.59M |
| Operating gains losses | ---98K | ---- | ---- | 3,825.00%157K | -38.37%159K | --0 | --0 | ---2K | 118.56%4K | 47,009.09%258K |
| Depreciation and amortization | 2.45%877K | 1.53%862K | -3.52%849K | 90.25%3.44M | 46.72%851K | 58.81%856K | 85.37%849K | 284.28%880K | 201.58%1.81M | 109.46%580K |
| Other non cash items | 0.00%43K | 0.00%41K | 0.00%42K | 221.90%167K | 117.52%41K | 2.38%43K | -21.15%41K | 1,300.00%42K | ---137K | ---234K |
| Change In working capital | -617.07%-1.27M | -6,095.00%-2.48M | 44.42%-274K | -362.36%-934K | -140.90%-647K | -84.03%246K | 98.19%-40K | 12.12%-493K | 108.11%356K | 76.65%1.58M |
| -Change in receivables | -148.10%-1.31M | 52.35%-447K | 314.39%298K | -153.19%-1.64M | -105.15%-38K | -776.67%-526K | -596.30%-938K | -106.27%-139K | 278.84%3.09M | 131.13%738K |
| -Change in prepaid assets | -54.42%340K | -51.79%216K | 27.63%-998K | 106.93%25K | -76.14%210K | -32.30%746K | 134.38%448K | -32.60%-1.38M | -81.45%-361K | 23.07%880K |
| -Change in payables and accrued expense | 1.86%1.2M | -145.85%-658K | 215.52%1.49M | 237.45%1.36M | -89.74%31K | 48.55%1.18M | 260.16%1.44M | -8.41%-1.29M | -141.99%-988K | -59.79%302K |
| -Change in other current liabilities | -11.69%-793K | -10.40%-775K | -13.65%-741K | -279.32%-2.79M | -114.20%-724K | -139.06%-710K | -260.00%-702K | -786.32%-652K | -125.29%-735K | -105.27%-338K |
| -Change in other working capital | -61.12%-717K | -187.63%-814K | -110.86%-322K | 427.44%2.11M | ---126K | ---445K | ---283K | 559.84%2.97M | 91.91%-645K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 3.49%-7.53M | 3.67%-9.99M | 9.68%-9.78M | 4.41%-39.96M | -4.22%-10.96M | -13.51%-7.8M | 19.28%-10.37M | 6.39%-10.83M | -7.64%-41.81M | 1.23%-10.51M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -98.04%98K | -100.20%-10K | -100.37%-55K | 201.59%25M | 0 | 116.94%5M | 8,164.52%5M | 55,662.96%15M | -370.19%-24.61M | 978,177.89%5M |
| Net PPE purchase and sale | --98K | ---10K | -2,850.00%-55K | 101.21%2K | --0 | --0 | --0 | 107.41%2K | 81.49%-165K | -295.69%-1K |
| Net investment purchase and sale | --0 | --0 | --0 | 202.27%25M | --0 | 116.98%5M | --5M | --15M | -344.45%-24.45M | --5M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -98.04%98K | -100.20%-10K | -100.37%-55K | 201.59%25M | --0 | 116.94%5M | 8,164.52%5M | 55,662.96%15M | -370.19%-24.61M | 978,177.89%5M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 114.01%9.82M | -147.60%-1M | 506.70%2.35M | -77.90%11.86M | -82.55%4.78M | 51,088.89%4.59M | -81.09%2.1M | -97.44%388K | 178.99%53.66M | 271.20%27.4M |
| Net issuance payments of debt | 0.00%-1M | ---1M | ---1M | -120.00%-2M | ---1M | ---1M | --0 | --0 | --10M | --0 |
| Net common stock issuance | 93.61%10.82M | --0 | --3.35M | -65.94%13.39M | -74.53%5.78M | --5.59M | -81.85%2.02M | --0 | 126.06%39.3M | 223.04%22.7M |
| Proceeds from stock option exercised by employees | --0 | --0 | --0 | -89.94%473K | --0 | --0 | --85K | --388K | 80.85%4.7M | 773.96%4.7M |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 54.54%-341K | 100.55%1K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 114.01%9.82M | -147.60%-1M | 506.70%2.35M | -77.90%11.86M | -82.55%4.78M | 51,088.89%4.59M | -81.09%2.1M | -97.44%388K | 178.99%53.66M | 271.20%27.4M |
| Net cash flow | ||||||||||
| Beginning cash position | -43.11%30.18M | -26.88%41.18M | -5.99%48.67M | -19.77%51.76M | 83.56%54.84M | -19.95%53.05M | -17.27%56.32M | -19.77%51.76M | -13.99%64.52M | -55.92%29.88M |
| Current changes in cash | 33.63%2.39M | -236.39%-11M | -264.25%-7.49M | 75.71%-3.1M | -128.22%-6.18M | 104.92%1.79M | -81.57%-3.27M | 28.15%4.56M | -21.55%-12.76M | 770.93%21.89M |
| End cash Position | -40.61%32.57M | -43.11%30.18M | -26.88%41.18M | -5.99%48.67M | -5.99%48.67M | 83.56%54.84M | -19.95%53.05M | -17.27%56.32M | -19.77%51.76M | -19.77%51.76M |
| Free cash flow | 3.50%-7.53M | 3.58%-10M | 9.18%-9.84M | 4.80%-39.96M | -4.21%-10.96M | -12.23%-7.8M | 19.69%-10.37M | 6.61%-10.83M | -5.60%-41.98M | 1.22%-10.52M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data